In brief
- The U.S. Department of Defense is funding two clinical trials of MDMA-assisted therapy for PTSD with $9.8 million, targeting active-duty military personnel rather than just retired veterans.
- The studies, conducted by the Walter Reed National Military Medical Center and the STRONG STAR consortium (Emory University), will combine MDMA with Massed Prolonged Exposure and aim to recruit approximately 186 participants.
- The debate extends beyond clinical concerns: several specialists are questioning the logic of treating combat trauma only to return the individual to the front lines that caused it.
The U.S. military has decided to invest directly in MDMA-assisted therapy research, but with a twist compared to previous trials: the stated goal this time is not only to alleviate the suffering of those who have left the service, but to treat post-traumatic stress disorder (PTSD) in active-duty soldiers so they can continue their military careers. The news, reported in mid-July by science media, has reignited the debate over the limits and implications of using psychedelics for the purpose of “readapting” personnel to service.
Two trials, one stated goal
The Department of Defense has committed $9.8 million, split equally between the Walter Reed National Military Medical Center and the STRONG STAR consortium at Emory University, led by researchers Alan Peterson and Barbara Rothbaum. Both trials will combine MDMA sessions with Massed Prolonged Exposure, a validated exposure therapy protocol commonly used in the military for PTSD. The Multidisciplinary Association for Psychedelic Studies (MAPS) is participating by providing specialized training to the therapists who will conduct the sessions—a point that the researchers themselves identify as a major bottleneck, as very few professionals within the military healthcare system have experience guiding full-day sessions with real-time trauma processing.
What is known about the design and timeline
According to information available so far, both studies plan to recruit a total of approximately 186 active-duty military personnel with mild to severe PTSD. The effective start date is projected for 2027, once therapist training phases and internal regulatory approvals are completed. This is not a currently available treatment: MDMA still lacks FDA approval for PTSD following the rejection of Lykos Therapeutics’ application in 2024, and these military trials are research, not a generalized clinical offering for the troops.
What it implies
It is useful to separate two levels. On the strictly clinical side, adding this design to the existing evidence on MDMA and PTSD is good news for those who have been pointing out the lack of effective options for combat trauma for years, although results will take years to arrive and there is no specific efficacy or safety data for this cohort yet. On the ethical level, the trial’s framework itself raises legitimate questions, as noted by specialists consulted by the scientific press: treating trauma with the explicit goal of returning the person to the environment that generated it is not the same as treating it to improve their well-being and civilian life. From a harm reduction perspective, neither is incompatible with scientific rigor, but it is important that those participating in these trials clearly understand the institutional purpose for which the treatment they are receiving is being researched.
Source
- Science Norway. “Want to offer MDMA therapy to soldiers with PTSD so they can defend their country for longer”. Science Norway, July 15, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
